An Egyptian pharmaceutical firm, Minapharm, is developing a potential vaccine against the Bundibugyo strain of the Ebola virus raging in the Democratic Republic of Congo. Backed by up to $16.5 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI), the candidate vaccine aims to address a deadly strain currently lacking specific licensed countermeasures.
In Plain English: The Clinical Takeaway
- The Target: The vaccine candidate focuses exclusively on the Bundibugyo species of the Ebola virus, which is currently driving the largest outbreak ever faced by the Democratic Republic of Congo.
- The Mechanism: Developed using a Modified Vaccinia Ankara (MVA) platform by Berlin-based ProBioGen, the shot is designed to provoke both B-cell and T-cell immune responses for long-lasting immunity.
- The Pipeline: The $16.5 million CEPI grant will advance the candidate through laboratory phases and into a Phase 1 clinical trial—small-scale human testing to evaluate safety and immunogenicity—expected to take place in Africa.
Expanding the Pipeline Against the Bundibugyo Strain
The Coalition for Epidemic Preparedness Innovations announced a joint funding agreement with Minapharm to accelerate the development of an experimental vaccine targeting the Bundibugyo species of Ebola.
The candidate vaccine is engineered by ProBioGen, a Berlin-based subsidiary of Minapharm. It represents the fifth Bundibugyo candidate vaccine currently backed by CEPI. Funding totaling up to $16.5 million is allocated to push the candidate out of preclinical laboratory stages and into Phase 1 clinical trials, which involve initial safety and immunogenicity assessments in human subjects on the African continent.
Technological Diversity in the Global Vaccine Race
Deploying a variety of vaccine technologies is critical to maximizing the probability of identifying a safe, efficacious tool against the virus. CEPI’s portfolio relies on multiple platforms across different developers. Moderna is utilizing messenger RNA (mRNA) technology; the University of Oxford and the Serum Institute of India are employing the ChAdOx viral vector platform; and Hilleman Laboratories alongside Public Health Vaccines are utilizing recombinant vesicular stomatitis virus (rVSV) technology.
Minapharm’s candidate stands apart by utilizing the Modified Vaccinia Ankara (MVA) vector platform. According to published joint statements, it is the sole candidate in this current CEPI cohort designed specifically to elicit both humoral (B-cell) and cellular (T-cell) immune responses, theoretically fostering sustained immunological memory.
| Developer / Institution | Vaccine Platform | Development Stage |
|---|---|---|
| Minapharm (ProBioGen) | Modified Vaccinia Ankara (MVA) | Preclinical / Advancing to Phase 1 |
| Moderna | mRNA Technology | Various Stages (CEPI Portfolio) |
| University of Oxford & Serum Institute of India | ChAdOx Platform | Various Stages (CEPI Portfolio) |
| Hilleman Laboratories | rVSV Technology | Various Stages (CEPI Portfolio) |
| Public Health Vaccines | rVSV Technology | Various Stages (CEPI Portfolio) |
Public Health Stakes and Regional Leadership
The urgency of diversifying countermeasures stems from the sheer velocity of transmission. “Bundibugyo virus is now driving the largest Ebola outbreak DRC has ever faced,” noted Jean Kaseya, head of the Africa Centres for Disease Control and Prevention (Africa CDC), highlighting the public health emergency. Kaseya emphasized the strategic importance of regional manufacturing capacity, stating that a candidate advanced by an African company represents a vital capability for the continent to develop and manufacture its own protective health tools.
Experts have endorsed a full-scale human trial in the DRC evaluating the approved Ervebo vaccine—traditionally deployed against the Zaire strain—to determine if it offers sufficient cross-protection against the Bundibugyo variant, building on promising early animal trial data.
Contraindications & When to Consult a Doctor
Because Minapharm’s MVA candidate vaccine is presently entering Phase 1 clinical trials, it is not yet available for public distribution, and clinical contraindications will be formally established as human safety data emerges.
References
- World Health Organization (WHO). Ebola virus disease fact sheet and outbreak updates. Available via WHO Official Portal.
- Coalition for Epidemic Preparedness Innovations (CEPI). R&D pipeline and funding announcements for Bundibugyo Ebola virus candidates. Available via CEPI News.
- Africa Centres for Disease Control and Prevention (Africa CDC). Public health surveillance reports on the Democratic Republic of Congo outbreaks. Available via Africa CDC.
Worth a look
